Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review.
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer morbidity and mortality. Adjuvant chemotherapy improves survival in resected early-stage NSCLC. However, a significant proportion of patients with early-stage lung cancer are cured by surgery alone. There are no reliable clinical or molecular markers to predict outcomes after surgery in early-stage NSCLC. Positron emission tomography with 2-[F]fluoro-2-deoxy-D-glucose (FDG-PET) improves the accuracy of staging work-up in NSCLC. The standardized uptake value, a commonly used semiquantitative measure of FDG uptake, correlates with tumor doubling time and indices of cell cycling. Therefore, FDG-PET may be a useful predictor of outcome independent of its role in tumor staging. In this review, we critically examine the published studies on the utility of FDG-PET as a prognostic tool in patients with NSCLC and provide direction for future research.
Pillot
Giancarlo
G
Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Siegel
Barry A
BA
Govindan
Ramaswamy
R
D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging*; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18